肠道菌群和抗生素与肾结石的形成

邱瑾; 刘剑新; 钟薏

doi:10.13201/j.issn.1001-1420.2020.12.016

肠道菌群和抗生素与肾结石的形成

- 1. 上海中医药大学附属上海市中西医结合医院泌尿外科(上海, 200082);
- 2. 上海中医药大学附属上海市中西医结合医院肿瘤科
基金项目:
上海市卫生健康委员会卫生行业临床研究专项(No:201940426)

详细信息

通讯作者: 刘剑新,E-mail:ljx6898@sina.com

中图分类号: R692.4

收稿日期: 2019-07-15

Intestinal flora, antibiotics and formation of kidney stones

- 1. Department of Urology, Shanghai Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200082, China;
- 2. Department of Oncology, Shanghai Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

More Information

Corresponding author: LIU Jianxin, E-mail: ljx6898@sina.com

Received Date: 15 July 2019

摘要

摘要: 肾结石是一种常见的泌尿系统疾病,其形成机制较为复杂,目前研究发现肾结石的形成与肠道微生物有关,如产甲酸草酸杆菌、双歧杆菌、乳酸杆菌、大肠埃希氏菌等,同时发现抗生素的使用易增加肾结石形成风险,本文就肠道菌群、抗生素与肾结石形成之间的关系作一综述。
- 肾结石 /
- 产甲酸草酸杆菌 /
- 益生菌 /
- 大肠埃希氏菌 /
- 抗生素
Abstract: Kidney stones are a common urinary system disease, and its formation mechanism is complicated. The current studies found that the formation of kidney stones was related to intestinal microbes, such as Oxalobacter formigenes, bifidobacteria, lactobacilli, Escherichia coli, etc. At the same time, it is found that the use of antibiotics is likely to increase the risk of kidney stone formation. This article reviews the relationship between intestinal flora, antibiotics and the formation of kidney stones.
- kidney stones /
- oxalobacter formigenes /
- probiotics /
- escherichia coli /
- antibiotics

HTML全文

参考文献(39)

[1]	叶章群,周辉.泌尿系结石基础研究及临床新进展[J].中华泌尿外科杂志,2017,38(9):644-649.
[2]	Trinchieri A,Montanari E.Biochemical and dietary factors of uric acid stone formation[J].Urolithiasis,2018,46(2):167-172.
[3]	Kinsey L,Burden S.A survey of people with inflammatory bowel disease to investigate their views of food and nutritional issues[J].Eur J Clin Nutr,2016,70(7):852-854.
[4]	Barczynska R,Kapusniak J,Litwin M,et al.Dextrins from Maize Starch as Substances Activating the Growth of Bacteroidetes and Actinobacteria Simultaneously Inhibiting the Growth of Firmicutes,Responsible for the Occurrence of Obesity[J].Plant Foods Hum Nutr,2016,71(2):190-196.
[5]	Felizardo RJF,Watanabe IKM,Dardi P,et al.The interplay among gut microbiota,hypertension and kidney diseases:The role of short-chain fatty acids[J].Pharmacol Res,2019,141:366-377.
[6]	杜伟,李东,宋小松,等.泌尿系结石成分与代谢异常的临床研究[J].中华肥胖与代谢病电子杂志,2018,4(1):35-39.
[7]	Sarica K.Obesity and stones[J].Curr Opin Urol,2019,29(1):27-32.
[8]	Trinchieri A.Body fatness,diabetes,physical activity and risk of kidney stones:a systematic review and meta-analysis of cohort studies[J].Eur J Epidemiol,2019,34(12):1175-1176.
[9]	Cordeu CA,Velilla-Zancada SM.Relationship between arterial hypertension and nephrolithiasis[J].Semergen,2019,45(8):e47-e48.
[10]	His RS,Spieker AJ,Stoller ML,et al.Coronary Artery Calcium Score and Association with Recurrent Nephrolithiasis:The Multi-Ethnic Study of Atherosclerosis[J].J Urol,2016,195(4 Pt 1):971-976.
[11]	Cai C,Mai Z,Deng T,et al.Impact of dyslipidemia on 24-h urine composition in adults without urolithiasis[J].Lipids Health Dis,2018,17(1):250.
[12]	Goulet O.Potential role of the intestinal microbiota in programming health and disease[J].Nutr Rev,2015,73 Suppl 1:32-40.
[13]	Chen YY,Chen DQ,Chen L,et al.Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease[J].J Transl Med,2019,17(1):5.
[14]	叶章群,刘浩然.泌尿系结石的诊断治疗进展[J].临床外科杂志,2017,25(2):85-88.
[15]	Hatch M.Gut microbiota and oxalate homeostasis[J].Ann Transl Med,2017,5(2):36.
[16]	咸晓莹,谢远亮,叶娟,等.肾结石患者肠道内草酸降解细菌的定量检测[J].基因组学与应用生物学,2016,35(9):2222-2228.
[17]	Jiang T,Chen W,Cao L,et al.Abundance,Functional,and Evolutionary Analysis of Oxalyl-Coenzyme A Decarboxylase in Human Microbiota[J].Front Microbiol,2020,11:672.
[18]	Li X,Ellis ML,Knight J.Oxalobacter formigenes Colonization and Oxalate Dynamics in a Mouse Model[J].Appl Environ Microbiol,2015,81(15):5048-5054.
[19]	Ticinesi A,Milani C,Guerra A,et al.Understanding the gut-kidney axis in nephrolithiasis:an analysis of the gut microbiota composition and functionality of stone formers[J].Gut,2018,67(12):2097-2106.
[20]	Miller AW,Choy D,Penniston KL,et al.Inhibition of urinary stone disease by a multi-species bacterial network ensures healthy oxalate homeostasis[J].Kidney Int,2019,96(1):180-188.
[21]	Suryavanshi MV,Bhute SS,Jadhav SD,et al.Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures[J].Sci Rep,2016,6:34712.
[22]	Sun NY,Gao Y,Yu HJ.Genome Sequence of Oxalobacter formigenes Strain SSYG-15[J].Microbiol Resour Announc,2019,8(42):e01059-19.
[23]	Hatch M,Allison MJ,Yu F,et al.Genome Sequence of Oxalobacter formigenes Strain OXCC13[J].Genome Announc,2017,5(28):e00534-17.
[24]	Hatch M,Allison MJ,Yu F,et al.Genome Sequence of Oxalobacter formigenes Strain HC-1[J].Genome Announc,2017,5(27):e00533-17.
[25]	Peck AB,Canales BK,Nguyen CQ.Oxalate-degrading microorganisms or oxalate-degrading enzymes:which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?[J].Urolithiasis,2016,44(1):45-50.
[26]	Milliner D,Hoppe B,Groothoff J.A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria[J].Urolithiasis,2018,46(4):313-323.
[27]	Jairath A,Parekh N,Otano N,et al.Oxalobacter formigenes:Opening the door to probiotic therapy for the treatment of hyperoxaluria[J].Scand J Urol,2015,49(4):334-337.
[28]	Hoppe B,Pellikka PA,Dehmel B,et al.Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease:a Phase II study[J].Nephrol Dial Transplant,2020:gfaa135.
[29]	Paul E,Albert A,Ponnusamy S,et al.Designer probiotic Lactobacillus plantarum expressing oxalate decarboxylase developed using group II intron degrades intestinal oxalate in hyperoxaluric rats[J].Microbiol Res,2018,215:65-75.
[30]	Klimesova K,Whittamore JM,Hatch M.Bifidobacterium animalis subsp.lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria[J].Urolithiasis,2015,43(2):107-117.
[31]	Wang H,Mei L,Deng Y,et al.Lactobacillus brevis DM9218 ameliorates fructose-induced hyperuricemia through inosine degradation and manipulation of intestinal dysbiosis[J].Nutrition,2018,62:63-73.
[32]	Stern JM,Moazami S,Qiu Y,et al.Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers[J].Urolithiasis,2016,44(5):399-407.
[33]	Tang R,Jiang Y,Tan A,et al.16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones[J].Urolithiasis,2018,46(6):503-514.
[34]	Amimanan P,Tavichakorntrakool R,Fong-Ngern K,et al.Elongation factor Tu on Escherichia coli isolated from urine of kidney stone patients promotes calcium oxalate crystal growth and aggregation[J].Sci Rep,2017,7(1):2953.
[35]	Darisipudi MN,Knauf F.An update on the role of the inflammasomes in the pathogenesis of kidney diseases[J].Pediatr Nephrol,2016,31(4):535-544.
[36]	Liu M,Nazzal L.Enteric hyperoxaluria:role of microbiota and antibiotics[J].Curr Opin Nephrol Hypertens,2019,28(4):352-359.
[37]	Joshi S,Goldfarb DS.The use of antibiotics and risk of kidney stones[J].Curr Opin Nephrol Hypertens,2019,28(4):311-315.
[38]	Kharlamb V,Schelker J,Francois F,et al.Oral antibiotic treatment of Helicobacter pylori leads to persistently reduced intestinal colonization rates with Oxalobacter formigenes[J].J Endourol,2011,25(11):1781-1785.
[39]	Tasian GE,Jemielita T,Goldfarb DS,et al.Oral Antibiotic Exposure and Kidney Stone Disease[J].J Am Soc Nephrol,2018,29(6):1731-1740.